A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC

A Prospective, Single Arm Clinical Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in the First Line Treatment of Patients With Locally Advanced or Metastastic Fumarate Hydratase Deficient Renal Cell Carcinoma

FHRCC is a rare kind of renal cell carcinoma with a morbidity of 1/2000000 per year.Although several combination therapies demonstrated possible efficacy in this population. No standard treatment has been approved. The purpose of this study is to evaluate the efficacy and safety of Lenvatinib in combination with tislelizumab in the first line treatment of patients with locally advanced/metastatic FHRCC.

Study Overview

• Status: Completed
• Conditions: Fumarate Hydratase Deficient Renal Cell Carcinoma
• Intervention / Treatment: Biological: Tislelizumab; Drug: Lenvatinib

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China
      • Ethics Committee of Shanghai Renji Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Fully understand and voluntarily sign the informed consent form and agree to receive treatment, examination and follow-up as required by the study protocol;
2. Age ≥ 18, < 80 years, male or female;
3. ECOG score ≤2;
4. unresectable or recurrent metastatic FH-deficient renal cell carcinoma not previously treated with systemic antitumor therapy, as confirmed by histology. Prior cytokine therapy is allowed;
5. At least 1 measurable tumor lesion according to RECIST 1.1 criteria. The lesion that has received prior radiotherapy and progressed again is allowed as a target lesion;
6. agree to provide blood and urine samples and previous archived or fresh tumor tissue samples.
7. Demonstrates adequate organ function.
8. Female subjects of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first dose. participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 180 days after the last dose of study drug.

Exclusion Criteria:

1. Prior treatment with agents targeting VEGF, VEGFR, or mTOR, including but not limited to sunitinib, axitinib, pazopanib, sorafenib, cabozantinib, lenvatinib, bevacizumab, anlotinib, or everolimus;
2. Prior treatment with anti-PD-1, PD-L1 or CTLA-4 antibodies;
3. Participants who are using other investigational agents or who had received investigational drugs <=4 weeks prior to study treatment start;
4. Received major surgery or is recovering from surgery (as judged by the investigator) within 4 weeks;
5. Received Chinese herbal or proprietary Chinese medicine preparation with an antitumor indication within 2 weeks;
6. Requirement of adrenocorticosteroids (>10 mg prednisone or equivalent daily) or other immunosuppressive systemic therapy within 2 week; inhalation of >10 mg prednisone or equivalent daily, but without active autoimmune disease may participate in this study;
7. History of organ transplantation or conditions requiring long-term adrenocorticosteroid or immunosuppressive therapy
8. Hypothyroidism, adrenal or pituitary gland function that can be controlled with hormone replacement therapy, type I diabetes mellitus, psoriasis or vitiligo that do not require systemic therapy may be enrolled in the study;
9. Didn't recover from prior antineoplastic therapy, grade 0 to 1 as defined by NCI-CTCAE 5.0 (except alopecia), or levels specified in the inclusion/exclusion criteria. Irreversible toxicity that is not expected to be exacerbated by the study drug can be enrolled;
10. The presence of other malignancies that have progressed or require treatment within 5 years (excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or cured carcinoma in situ, such as carcinoma in situ of the breast, prostate cancer: subjects with limited low-risk prostate cancer (≤ T2a, Gleason score ≤ 6, PSA < 10ng/ml) who have received radical treatment and no PSA biochemical (those with recurrence may participate in this study);
11. History of active central nervous system (CNS) metastases or baseline phase imaging showing CNS metastases within 30 days prior to the first dose. Subjects with prior surgical or radiation treatment for brain or meningeal metastases who have maintained clinical stability for ≥ 3 months by screening and have discontinued systemic hormone therapy (dose > 10 mg/day of prednisone or other equivalent hormone) for > 4 weeks may be enrolled. Subjects may be enrolled in this study if the subject's CNS metastases can be treated to meet the requirements of the enrollment criteria and if the subject's CNS symptoms have returned to ≤ grade 1 for at least 2 weeks prior to enrollment (except for residual signs or symptoms related to CNS treatment);
12. Poorly controlled hypertension: SBP ≥ 150 mmHg and/or DBP ≥ 90 mmHg;
13. Any one or more of the following cardiovascular disease states within the last 6 months: myocardial infarction; unstable angina; endoluminal angioplasty or coronary stenting; coronary/peripheral artery bypass graft; NYHA cardiac function class 3-4; congestive heart failure; cerebrovascular accident including transient ischemic attack;
14. Heart rate corrected QT interval (QTc) ≥ 480 ms;
15. History of active bleeding or other severe bleeding within 1 month;
16. Deep vein thrombosis or pulmonary embolism within 6 months;
17. Arterial embolism within the last 12 months;
18. Clinically significant gastrointestinal abnormalities, including: malabsorption, total gastrectomy, or any condition that may interfere with the absorption of oral medications; active ulcers treated within 6 months; active gastrointestinal bleeding (vomiting blood, blood in stool, or black stool) within 3 months by endoscopy; metastatic lesions in the gastrointestinal tract suspected of bleeding, inflammatory bowel disease, ulcerative colitis Gastrointestinal perforation or other gastrointestinal disorders that increase the risk of perforation;
19. The presence of (non-infectious) pneumonia/interstitial lung disease requiring adrenocorticosteroid therapy, either previously or currently
20. Presence of active infection requiring systemic therapy, presence of human immunodeficiency virus (HIV) infection (known HIV antibody positivity), presence of active HBV infection (HBsAg positive, or HBcAb positive but HBsAg negative, additional DNA quantification is required and results that do not exceed the upper limit of normal laboratory values can be enrolled), presence of active HCV infection (previous HCV infected patients with negative HCV RNA test results during the screening period can be enrolled);
21. Live virus vaccinations within the last 1 month, including but not limited to mumps, rubella, measles, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccines, excluding inactivated virus vaccines;
22. A history of severe drug allergy, including but not limited to antibody drugs and small molecule targeted drugs;
23. Known psychiatric illness or history of substance abuse;
24. Presence of unhealed wounds;
25. The presence of any medical history or current evidence of disease, treatment or laboratory abnormality that, in the investigator's judgment, could confound the results of the trial, interfere with the subject's participation in the full trial, or is not in the subject's best interest to participate in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tislelizumab+Lenvatinib combination therapy; Participants receive tislelizumab 200 mg intravenously every 3 weeks PLUS lenvatinib 20mg orally once daily.	Biological: Tislelizumab; Intravenous infusion; Drug: Lenvatinib; Oral tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)	ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1.	Up to approximately 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)	PFS was defined as the time from enrollment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.	Up to approximately 24 months
Overall Survival (OS)	OS was defined as the time from enrollment to death due to any cause.	Up to approximately 24 months
Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)	DCR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions), Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters), or Stable Disease (SD) per RECIST 1.1 for ≥6 months.	Up to approximately 24 months
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)	DOR was defined as the time from first documented evidence of a Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 until progressive disease (PD) or death due to any cause, whichever occurred first.	Up to approximately 24 months
Overall Survival (OS) Rate at Month 12 in All Participants	The OS rate was determined for all participants at Month 12 and was defined as the time from enrollment to death due to any cause.	Month 12
Overall Survival (OS) Rate at Month 24 in All Participants	The OS rate was determined for all participants at Month 24 and was defined as the time from enrollment to death due to any cause.	Month 24
Number of Participants Who Experienced an Adverse Event (AE)	An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment.	Up to approximately 24 months

Collaborators and Investigators

• Sponsor: RenJi Hospital

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2023
• Primary Completion (Actual): December 30, 2025
• Study Completion (Actual): December 31, 2025

Study Registration Dates

• First Submitted: May 18, 2023
• First Submitted That Met QC Criteria: May 18, 2023
• First Posted (Actual): May 26, 2023

Study Record Updates

• Last Update Posted (Actual): September 10, 2026
• Last Update Submitted That Met QC Criteria: September 7, 2026
• Last Verified: September 1, 2026

More Information

Terms related to this study

• Keywords: PD-1 checkpoint inhibitor; FHRCC
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Carcinoma, Renal Cell; Carcinoma; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Immunological; Protein Kinase Inhibitors; lenvatinib; tislelizumab
• Other Study ID Numbers: LENTIS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No plan to share IPD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No